Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: March 22, 2012
Last updated: February 23, 2017
Last verified: February 2017
This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.

Condition Intervention Phase
Growth Hormone Disorder
Adult Growth Hormone Deficiency
Drug: somatropin
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: Randomized Cross Over Double Blind Versus Placebo Trial Followed by an Open Phase Studying Effect of Norditropin® on Left Ventricular Mass of Growth Hormone Deficient Adult Patients

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Left ventricular mass measured with ultrasonography

Secondary Outcome Measures:
  • Ventricular function indices assessed by cardiac ultrasonography
  • Bone mineral density and body composition assessed by DEXA (Dual Energy X-Ray Absorptiometry)
  • Quality of life using EQ5D (European Quality of Life 5 Dimensions) scales
  • IGF-I (Insulin-Like Growth Factor I) concentration

Enrollment: 22
Actual Study Start Date: October 21, 1998
Study Completion Date: December 1, 2002
Primary Completion Date: December 1, 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Somatropin Drug: somatropin
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
Placebo Comparator: Placebo Drug: placebo
Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Childhood or adult onset growth hormone deficiency (GHD)
  • GHD evidenced by two stimulation tests
  • Duration of GHD at least 5 years
  • Other hormone deficiencies associated with growth hormone deficiency

Exclusion Criteria:

  • Pregnancy or pregnancy desired during the suggested duration of the study
  • Personal history of colonic polyp or family history of colonic polyposis
  • Known insulin-dependent or non-insulin-dependent diabetes
  • Cardiovascular disease, left ventricular hypertrophy from other aetiology, recent auricular or ventricular arrhythmia, history of vascularisation by aortocoronary bypass significative mitral or aortic valvular disease, preexcitation syndrome, auriculoventricular conduction delay, bradycardia-tachycardia syndrome, left ventricular mass interfering treatment
  • BMI (Body Mass Index) at least 30
  • Growth hormone treatment during the 24 months prior to inclusion, history of treatment with extractive pituitary growth hormone, allergy or suspected allergy to somatropin therapy
  • Patient who has participated in a different clinical study within the past two months
  • Any condition which, in the opinion of the Investigator or the Scientific Committee, may interfere with successful implementation of the study
  • Notion of breast cancer for the mother or the sister
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01562834

Novo Nordisk Investigational Site
ANGERS cedex 09, France, 49033
Novo Nordisk Investigational Site
Boisguillaume, France, 76233
Novo Nordisk Investigational Site
Brest, France, 29609
Novo Nordisk Investigational Site
Caen, France, 14033
Novo Nordisk Investigational Site
Grenoble, France, 38043
Novo Nordisk Investigational Site
Le Kremlin-bicetre, France, 94275
Novo Nordisk Investigational Site
Lille, France, 59037
Novo Nordisk Investigational Site
Lorient, France, 56322
Novo Nordisk Investigational Site
Lyon, France, 69394
Novo Nordisk Investigational Site
Lyon, France, 69437
Novo Nordisk Investigational Site
MARSEILLE Cédex 05, France, 13385
Novo Nordisk Investigational Site
MONTPELLIER cedex 5, France, 34295
Novo Nordisk Investigational Site
Nantes, France, 44000
Novo Nordisk Investigational Site
Nantes, France, 44093
Novo Nordisk Investigational Site
Nice, France, 06002
Novo Nordisk Investigational Site
Paris, France, 75010
Novo Nordisk Investigational Site
Paris, France, 75015
Novo Nordisk Investigational Site
Paris, France, 75571
Novo Nordisk Investigational Site
Reims, France, 51092
Novo Nordisk Investigational Site
Rennes, France, 35056
Novo Nordisk Investigational Site
Strasbourg, France, 67098
Novo Nordisk Investigational Site
TOULOUSE cedex, France, 31054
Novo Nordisk Investigational Site
Tours, France, 37044
Novo Nordisk Investigational Site
Vandoeuvre Les Nancy, France, 54511
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT01562834     History of Changes
Other Study ID Numbers: GHDADULT/F/1/F
Study First Received: March 22, 2012
Last Updated: February 23, 2017

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on May 23, 2017